Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial.
Mavoko HM, Nabasumba C, da Luz RI, Tinto H, D'Alessandro U, Kambugu A, Baraka V, Rosanas-Urgell A, Lutumba P, Van Geertruyden JP. Mavoko HM, et al. Lancet Glob Health. 2017 Jan;5(1):e60-e68. doi: 10.1016/S2214-109X(16)30236-4. Epub 2016 Nov 11. Lancet Glob Health. 2017. PMID: 27840069 Free article. Clinical Trial.
Different origin and dispersal of sulfadoxine-resistant Plasmodium falciparum haplotypes between Eastern Africa and Democratic Republic of Congo.
Baraka V, Delgado-Ratto C, Nag S, Ishengoma DS, Madebe RA, Mavoko HM, Nabasumba C, Lutumba P, Alifrangis M, Van Geertruyden JP. Baraka V, et al. Among authors: mavoko hm. Int J Antimicrob Agents. 2017 Apr;49(4):456-464. doi: 10.1016/j.ijantimicag.2016.12.007. Epub 2017 Feb 22. Int J Antimicrob Agents. 2017. PMID: 28237831
Impact of treatment and re-treatment with artemether-lumefantrine and artesunate-amodiaquine on selection of Plasmodium falciparum multidrug resistance gene-1 polymorphisms in the Democratic Republic of Congo and Uganda.
Baraka V, Mavoko HM, Nabasumba C, Francis F, Lutumba P, Alifrangis M, Van Geertruyden JP. Baraka V, et al. Among authors: mavoko hm. PLoS One. 2018 Feb 1;13(2):e0191922. doi: 10.1371/journal.pone.0191922. eCollection 2018. PLoS One. 2018. PMID: 29390014 Free PMC article. Clinical Trial.
Intimate Partners Violence against Women during a COVID-19 Lockdown Period: Results of an Online Survey in 7 Provinces of the Democratic Republic of Congo.
Ditekemena JD, Luhata C, Mavoko HM, Siewe Fodjo JN, Nkamba DM, Van Damme W, Ebrahim SH, Noestlinger C, Colebunders R. Ditekemena JD, et al. Among authors: mavoko hm. Int J Environ Res Public Health. 2021 May 12;18(10):5108. doi: 10.3390/ijerph18105108. Int J Environ Res Public Health. 2021. PMID: 34065852 Free PMC article.
Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial Resistance.
Moriarty LF, Nkoli PM, Likwela JL, Mulopo PM, Sompwe EM, Rika JM, Mavoko HM, Svigel SS, Jones S, Ntamabyaliro NY, Kaputu AK, Lucchi N, Subramaniam G, Niang M, Sadou A, Ngoyi DM, Muyembe Tamfum JJ, Schmedes SE, Plucinski MM, Chowell-Puente G, Halsey ES, Kahunu GM. Moriarty LF, et al. Among authors: mavoko hm. Am J Trop Med Hyg. 2021 Sep 7;105(4):1067-1075. doi: 10.4269/ajtmh.21-0214. Am J Trop Med Hyg. 2021. PMID: 34491220 Free PMC article. Clinical Trial.
13 results